Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1978 1
1979 3
1982 2
1991 2
1993 1
1995 1
1996 5
1997 1
1999 4
2000 4
2001 1
2002 2
2003 2
2004 1
2005 5
2006 1
2007 6
2008 3
2009 6
2010 8
2011 3
2012 6
2013 8
2014 4
2015 12
2016 8
2017 8
2018 5
2019 14
2020 16
2021 11
2022 11
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for martin macula
Search for Martin Macuha instead (1 results)
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Baker CW, et al. JAMA. 2019 May 21;321(19):1880-1894. doi: 10.1001/jama.2019.5790. JAMA. 2019. PMID: 31037289 Free PMC article. Clinical Trial.
IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). ...
IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME …
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Jhaveri CD, et al. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. N Engl J Med. 2022. PMID: 35833805 Free PMC article. Clinical Trial.
CONCLUSIONS: In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we found no evidence of a significant difference in visual outcomes over a 2-year period between aflibercept monotherapy and treatment with bev …
CONCLUSIONS: In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we …
[Idiopathic polypoidal vasculopathy].
Cifuentes-Canorea P, Asorey-García A, Perucho-Gonzalez L, Donate-López J, Santos-Bueso E. Cifuentes-Canorea P, et al. J Fr Ophtalmol. 2015 Jun;38(6):571. doi: 10.1016/j.jfo.2014.11.009. Epub 2015 Apr 15. J Fr Ophtalmol. 2015. PMID: 25890593 French. No abstract available.
Metasurface-enhanced light detection and ranging technology.
Juliano Martins R, Marinov E, Youssef MAB, Kyrou C, Joubert M, Colmagro C, Gâté V, Turbil C, Coulon PM, Turover D, Khadir S, Giudici M, Klitis C, Sorel M, Genevet P. Juliano Martins R, et al. Nat Commun. 2022 Sep 29;13(1):5724. doi: 10.1038/s41467-022-33450-2. Nat Commun. 2022. PMID: 36175421 Free PMC article.
Vitreomacular traction syndrome.
Martins TG, Martins TG, Rodriguez EE, Costa AL. Martins TG, et al. Einstein (Sao Paulo). 2015 Apr-Jun;13(2):334-5. doi: 10.1590/S1679-45082015AI2979. Epub 2015 May 1. Einstein (Sao Paulo). 2015. PMID: 25946051 Free PMC article. No abstract available.
Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis.
Cifuentes-González C, Rojas-Carabali W, Pérez ÁO, Carvalho É, Valenzuela F, Miguel-Escuder L, Ormaechea MS, Heredia M, Baquero-Ospina P, Adan A, Curi A, Schlaen A, Urzua CA, Couto C, Arellanes L, de-la-Torre A. Cifuentes-González C, et al. PLoS One. 2023 Apr 3;18(4):e0283845. doi: 10.1371/journal.pone.0283845. eCollection 2023. PLoS One. 2023. PMID: 37011101 Free PMC article.
Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR …
Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predomin …
New Treatment Modalities for Neovascular Age-Related Macular Degeneration.
Schlottmann PG, Alezzandrini AA, Zas M, Rodriguez FJ, Luna JD, Wu L. Schlottmann PG, et al. Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):514-519. doi: 10.22608/APO.2017258. Epub 2017 Sep 14. Asia Pac J Ophthalmol (Phila). 2017. PMID: 28933517 Free article. Review.
Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study.
Sarici K, Yordi S, Martin A, Lunasco L, Mugnaini C, Chu K, Moini H, Vitti R, Srivastava SK, Ehlers JP. Sarici K, et al. Ophthalmol Retina. 2023 Jun;7(6):543-552. doi: 10.1016/j.oret.2023.01.018. Epub 2023 Feb 2. Ophthalmol Retina. 2023. PMID: 36736895 Free article. Clinical Trial.
METHODS: A machine learning-enabled feature extraction system generated panretinal quantitative UWFA metrics, including leakage, ischemia, and microaneurysm (MA) burden. Zonal assessments were performed corresponding to the macula, midperiphery, and far periphery. MAIN OUT …
METHODS: A machine learning-enabled feature extraction system generated panretinal quantitative UWFA metrics, including leakage, ischemia, a …
Complement in removal of the dead - balancing inflammation.
Martin M, Blom AM. Martin M, et al. Immunol Rev. 2016 Nov;274(1):218-232. doi: 10.1111/imr.12462. Immunol Rev. 2016. PMID: 27782329 Review.
Disturbances in the complement-mediated clearance of dying cells result in persistence of autoantigens and development of autoimmune diseases like systemic lupus erythematosus, and may also be involved in development of age-related macula degeneration....
Disturbances in the complement-mediated clearance of dying cells result in persistence of autoantigens and development of autoimmune disease …
154 results